- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
AJMC® in the Press, April 14, 2023
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
An article by RealClear Health referenced a study published in the August 2022 issue of The American Journal of Managed Care® (AJMC®). The study, “Coverage With Evidence Development: Where Are We Now?” reviewed how CMS could improve its coverage with evidence development policy by increasing program transparency and clarifying the requirements and timelines for reporting.
A news roundup by the Healthcare Association of New York State highlighted a study published in the March 2023 issue of AJMC. The study, “Trends in Sepsis and Pneumonia During COVID-19: Lessons from BPCIA,” analyzed the changes in cost and utilization for sepsis or pneumonia episodes not related to COVID-19 prior to and during the pandemic as well as during the pandemic in patients with and without COVID-19.
The Breakdown: Breast Cancer Research Awareness Day
August 19th 2025Breast cancer is the second most common cancer among women and the second leading cause of cancer-related deaths among women in the US. In light of Breast Cancer Research Awareness Day, The American Journal of Managed Care® breaks down the most recent advancements in breast cancer prevention, screening, and therapies.
Listen
Hope on the Horizon for Underserved Patients With Multiple Myeloma: Joseph Mikhael, MD
August 12th 2025Explore the disparities in multiple myeloma treatment and how new initiatives aim to improve clinical trial participation among underrepresented patients during a conversation with Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO, chief medical officer of the International Myeloma Foundation.
Listen
Oral GC Dose Tapering for MG Linked to Efgartigimod Initiation
August 25th 2025Using US claims data, the authors evaluated oral glucocorticoid (GC) use at 5 time points during their retrospective analysis: 3 months before starting efgartigimod and 3, 6, 9, and 12 months after starting efgartigimod.
Read More
